Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of STN1013800 Ophthalmic Solution in Acquired Blepharoptosis
jRCT2031220394Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxymetazoline in acquired blepharoptosis (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change in MRD-1 from baseline to Day 14. Started Oct 2022; status: completed.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on jRCT2031220394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220394.